Individualising dual antiplatelet therapy after percutaneous coronary intervention: The IDEAL-PCI registry

BMJ Open

Volumn 4, Issue 10, 2014, Pages

  Christ, Günter ^a   Siller Matula, Jolanta M ^b   Francesconi, Marcel ^a   Dechant, Cornelia ^a   Grohs, Katharina ^a   Podczeck Schweighofer, Andrea ^a  

^a KAISER FRANZ JOSEF HOSPITAL   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PRASUGREL; TICAGRELOR; ADENOSINE; ANTITHROMBOCYTIC AGENT; PIPERAZINE DERIVATIVE; THIOPHENE DERIVATIVE; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ALGORITHM; ANTICOAGULANT THERAPY; ARTICLE; BIOLIMUS ELUTING STENT; BLEEDING; BLOOD CLOT LYSIS; CARDIOVASCULAR MORTALITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; DUAL ANTIPLATELET THERAPY; EVEROLIMUS ELUTING STENT; FEMALE; HEART DISEASE; HEART INFARCTION; HEMATOLOGY ANALYZER; HIGH ON TREATMENT PLATELET REACTIVITY; HUMAN; IMPEDANCE AGGREGOMETER; INTRACORONARY DRUG ADMINISTRATION; LOADING DRUG DOSE; MAJOR CARDIAC ADVERSE EVENT; MAJOR CLINICAL STUDY; MALE; MULTIPLE ELECTRODE AGGREGOMETRY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PERSONALIZED MEDICINE; PLATELET AGGREGATION ASSAY; PLATELET REACTIVITY; REGISTER; RISK FACTOR; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; THROMBOLYSIS IN MYOCARDIAL INFARCTION; ZOTAROLIMUS ELUTING STENT; ANALOGS AND DERIVATIVES; BLOOD; COHORT ANALYSIS; CORONARY ARTERY DISEASE; GRAFT OCCLUSION, VASCULAR; MIDDLE AGED; MYOCARDIAL INFARCTION; PROCEDURES; PROSPECTIVE STUDY; STENT; THROMBOCYTE; THROMBOCYTE AGGREGATION; TRANSLUMINAL CORONARY ANGIOPLASTY;

ACUTE CORONARY SYNDROME; ADENOSINE; AGED; ANGIOPLASTY, BALLOON, CORONARY; ASPIRIN; BLOOD PLATELETS; COHORT STUDIES; CORONARY ARTERY DISEASE; FEMALE; GRAFT OCCLUSION, VASCULAR; HUMANS; INDIVIDUALIZED MEDICINE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PIPERAZINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; REGISTRIES; STENTS; THIOPHENES; TICLOPIDINE;

EID: 84911445912     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-005781     Document Type: Article

References (29)

1. Tantry US, Bonello L, Aradi D, et al. Consensus and update on the definition of on-treatment platelet reactivity to ADP associated with ischemia and bleeding. J Am Coll Cardiol 2013;62:2261-73.
2. Aradi D, Storey RF, Komócsi A, et al.; on behalf of the Working Group on Thrombosis of the European Society of Cardiology. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J 2014;35:209-15.
3. Stone GW, Witzenbichler B, Weisz G, et al.; for the ADAPT-DES Investigators. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 2013;382:614-23.
4. Bonello L, Camoin-Jau L, Arques S, et al . Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008;51:1404-11.
5. Siller-Matula JM, Francesconi M, Dechant C, et al. Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study. Int J Cardiol 2013;167:2018-23.
6. Aradi D, Komócsi A, Price MJ, et al.; for the Tailored Antiplatelet Treatment Study Collaboration. Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis. Int J Cardiol 2013;167:2140-8.
7. Price MJ, Berger PB, Teirstein PS, et al.; for the Gravitas Investigators. Standard- vs. high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011;305:1097-105.
8. Collet JP, Cuisset T, Range G, et al.; for the ARCTIC Investigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012;367:2100-9.
9. Trenk D, Stone GW, Gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol 2012;59:2159-64.
10. Siller-Matula JM, Jilma B. Why have studies of tailored anti-platelet therapy failed so far? Thromb Haemost. 2013;110:628-31.
11. Bhatt DL, Stone GW, Mahaffey KW, et al.; for the CHAMPION PHOENIX Investigators. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 2013;368:1303-13.
12. Siller-Matula JM, Delle-Karth G, Christ G, et al. Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin. Int J Cardiol 2013;167:430-5.
13. Breet NJ, van Werkum JW, Bouman HJ, et al. High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention. Heart 2011;97:983-90.
14. Sibbing D, Braun S, Morath T, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009;53:849-56.
15. Siller-Matula JM, Christ G, Lang IM, et al. Multiple electrode aggregometry predicts stent thrombosis better than the VASP assay. J Thromb Haemost 2010;8:351-9.
16. Cutlip DE, Windecker S, Mehran R, et al.; for the Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-51.
17. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987;76:142-54.
18. Wiviott SD, Braunwald E, McCabe CH, et al.; for the TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15.
19. Wallentin L, Becker RC, Budaj A, et al.; for the PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57.
20. Christ G, Hafner T, Siller-Matula JM, et al. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy. Thromb Res 2013;132:e36-41.
21. Al-Azzam SI, Alzoubi KH, Khabour O, et al. The prevalence and factors associated with aspirin resistance in patients premedicated with aspirin. Acta Cardiol 2012;67:445-8.
22. Toth O, Calatzis A, Penz S, et al. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 2006;96:781-8.
23. Siller-Matula JM, Lang I, Christ G, et al. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008;52:1557-63.
24. Iqbal J, Sumaya W, Tatman V, et al. Incidence and predictors of stent thrombosis: a single-centre study of 5,833 consecutive patients undergoing coronary artery stenting. EuroIntervention 2013;9:62-9.
25. Brodie B, Pokharel Y, Garg A, et al. Predictors of early, late, and very late stent thrombosis after primary percutaneous coronary intervention with bare-metal and drug-eluting stents for ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 2012;5:1043-51.
26. Heestermans AA, van Werkum JW, Zwart B, et al. Acute and subacute stent thrombosis after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: incidence, predictors and clinical outcome. J Thromb Haemost 2010;8:2385-93.
27. Stone GW, Witzenbichler B, Guagliumi G, et al.; for the HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358:2218-30.
28. Cornelissen I, Palmer D, David T, et al. Roles and interactions among protease-activated receptors and P2ry12 in hemostasis and thrombosis. Proc Natl Acad Sci USA 2010;107:18605-10.
29. Kreutz RP, Breall JA, Kreutz Y, et al. Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependent on clopidogrel response. Thromb Res 2012;130:198-202.